1 min read

European Young Investigators Meeting (EYIM) – March 2026

European Young Investigators Meeting (EYIM) - 2026

Optimizationof blockeroligonucleotidesas therapiesto correct consequencesof deepintronicmutations.

Category

Published

March 1, 2026

Reading time

1 min read

Topic

Recognition

Publication

Press Release

Keep reading

Related news & insights

A proud moment for the entire Aceso Therapeutics team

🏆 A proud moment for the entire Aceso Therapeutics team: ACT-101 has been selected as a winner of the 2026 i-Lab Innovation Competition (28th edition), supported by Bpifrance under the

San Diego convention Center: June 22 – 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis

Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for

Get in touch

Partner with us to redefine cystic fibrosis care.

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

Email

Headquarters

Montpellier, France